• Citer

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

par Porta, C;Tortora, Giampaolo;Linassier, C;Papazisis, K;Awada, Ahmad ;Berthold, D;Maroto, J P;Powles, Trevor J;De Santis, Maria
Référence Medical oncology, 29, 3, page (1896-1907)
Publication Publié, 2012-09

Article révisé par les pairs

• Détails
• Contenu

Titre:	Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.
Auteur:	Porta, C; Tortora, Giampaolo; Linassier, C; Papazisis, K; Awada, Ahmad; Berthold, D; Maroto, J P; Powles, Trevor J; De Santis, Maria
Informations sur la publication:	Medical oncology, 29, 3, page (1896-1907)
Statut de publication:	Publié, 2012-09
Sujet CREF:	Cancérologie
Mots-clés:	Bevacizumab
	Everolimus
	Pazopanib
	RCC
	Renal cell carcinoma
	Sequence
	Sorafenib
	Sunitinib
	Temsirolimus
	Tyrosine kinase inhibitor
MeSH keywords:	Antineoplastic Agents -- therapeutic use
	Carcinoma, Renal Cell -- drug therapy
	Clinical Trials as Topic
	Drug Delivery Systems
	Humans
	Kidney Neoplasms -- drug therapy
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
	Review
	SCOPUS: re.j
Langue:	Anglais
Identificateurs:	urn:issn:1357-0560
	info:doi/10.1007/s12032-011-0016-8
	info:scp/84871517868
	info:pmid/21735145